Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer.

SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013 Jul; 34(7):1476-86.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.